Physician-Specific Maximum Acceptable Risk in Personalized Medicine: Implications for Medical Decision Making

Med Decis Making. 2018 Jul;38(5):593-600. doi: 10.1177/0272989X18758279. Epub 2018 Apr 3.

Abstract

Background: In discrete-choice experiments (DCEs), respondents are presented with a series of scenarios and asked to select their preferred choice. In clinical decision making, DCEs allow one to calculate the maximum acceptable risk (MAR) that a respondent is willing to accept for a one-unit increase in treatment efficacy. Most published studies report the average MAR for the whole sample, without conveying any information about heterogeneity. For a sample of psychiatrists prescribing drugs for a series of hypothetical patients with schizophrenia, this article demonstrates how heterogeneity accounted for in the DCE modeling can be incorporated in the derivation of the MAR.

Methods: Psychiatrists were given information about a group of patients' responses to treatment on the Positive and Negative Syndrome Scale (PANSS) and the weight gain associated with the treatment observed in a series of 26 vignettes. We estimated a random parameters logit (RPL) model with treatment choice as the dependent variable.

Results: Results from the RPL were used to compute the MAR for the overall sample. This was found to be equal to 4%, implying that, overall, psychiatrists were willing to accept a 4% increase in the risk of an adverse event to obtain a one-unit improvement of symptoms - measured on the PANSS. Heterogeneity was then incorporated in the MAR calculation, finding that MARs ranged between 0.5 and 9.5 across the sample of psychiatrists.

Limitations: We provided psychiatrists with hypothetical scenarios, and their MAR may change when making decisions for actual patients.

Conclusions: This analysis aimed to show how it is possible to calculate physician-specific MARs and to discuss how MAR heterogeneity could have implications for medical practice.

Keywords: discrete choice experiments; maximum-acceptable risk; personalized medicine; preference analysis; psychiatry.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antipsychotic Agents / adverse effects
  • Antipsychotic Agents / therapeutic use*
  • Choice Behavior*
  • Clinical Decision-Making*
  • Health Knowledge, Attitudes, Practice*
  • Humans
  • Interviews as Topic
  • Logistic Models
  • Physicians / psychology*
  • Precision Medicine
  • Risk
  • Schizophrenia / drug therapy*
  • Schizophrenic Psychology
  • Severity of Illness Index
  • Surveys and Questionnaires

Substances

  • Antipsychotic Agents